OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.06), reports.
Shares of OncoSec Medical (NASDAQ ONCS) traded up 9.52% on Wednesday, hitting $1.15. 1,483,808 shares of the stock traded hands. The stock’s market cap is $24.34 million. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The company’s 50 day moving average is $1.07 and its 200 day moving average is $1.06.
ONCS has been the topic of several recent analyst reports. Maxim Group reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Tuesday, October 10th. ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Finally, Dawson James reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Thursday, July 6th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $5.33.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.